BCEL logo

Atreca (BCEL) Stock

Profile

Full Name:

Atreca, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 June 2019

Indexes:

Not included

Website:

http://www.atreca.com

Description:

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$2.52(+14.58% YoY)

PE Ratio

-

Annual ROE

-123.92%

Annual Debt To Equity

0.81

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

June 27, 2024

Recent annual earnings:

Mar 29, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

14 Aug '23 Wedbush
Neutral
11 Aug '23 Stifel
Hold
11 Aug '23 HC Wainwright & Co.
Neutral
05 June '23 HC Wainwright & Co.
Buy
11 May '23 Stifel
Buy
11 May '23 HC Wainwright & Co.
Buy
30 Mar '23 Wedbush
Outperform
30 Mar '23 HC Wainwright & Co.
Buy
30 Mar '23 Evercore ISI Group
In-Line
30 Mar '23 EF Hutton
Buy

Screeners with BCEL included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$27.28
BCEL price is currently at an all-time high

Price Analysts Target

$2.00
BCEL price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

-43.97%
BCEL annual net profit is down -43.97% over the past 3 years

Annual EPS 3-Year Change

+40.85%
BCEL annual earnings per share is up +40.85% over the past 3 years

Annual EPS Estimate

-$2.04
BCEL annual earnings per share is currently +23.53% higher than the consensus analysts' forecast

Annual Operating Profit

-$98.30 M
BCEL annual operaing income is -$98.30 million

Annual Operating Profit 3-Year Change

-35.45%
BCEL annual operaing income is down -35.45% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-123.92%
BCEL annual return on equity is -123.92%

Annual ROA

-62.67%
BCEL annual return on assets is -62.67%

Annual EBIT

-$97.16 M
BCEL annual earnings before interest & taxes is -$97.16 million

Annual EBITDA

-$90.08 M
BCEL annual earnings before interest, taxes, depreciation & amortization is -$90.08 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

4.79
BCEL annual current ratio is 4.79

Annual Total Assets

$155.03 M
BCEL annual total assets is $155.03 million

Annual Current Assets

$78.03 M
BCEL annual total current assets is $78.03 million

Annual Total Liabilities

$76.62 M
BCEL annual total liabilities is $76.62 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

-37.9%
BCEL annual cash flow from operations is down -37.9% over the past 3 years

Annual CFI 3-Year Change

+144.97%
BCEL annual cash flow from investing activities is up +144.97% over the past 3 years

Annual CFF 3-Year Change

-97.02%
BCEL annual cash flow from financing activities is down -97.02% over the past 3 years

Annual FCF

-$81.61 M
BCEL annual free cash flow is -$81.61 million

Annual FCF 3-Year Change

-31.65%
BCEL annual free cash flow is down -31.65% over the past 3 years

Institutional Ownership

Similar stocks

Why Is Atreca (BCEL) Stock Up 85% Today?
Why Is Atreca (BCEL) Stock Up 85% Today?
Why Is Atreca (BCEL) Stock Up 85% Today?
BCEL
InvestorPlace11 January 2024

Atreca (NASDAQ: BCEL ) stock is rising higher on Thursday following news of a major stake in the clinical-stage biopharmaceutical company from an investment advisor. According to a filing with the Securities and Exchange Commission (SEC), Baker Bros.

Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
BCEL
Zacks Investment Research14 August 2023

Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.

3 Penny Stocks to Catapult You Into the Millionaires' Club
3 Penny Stocks to Catapult You Into the Millionaires' Club
3 Penny Stocks to Catapult You Into the Millionaires' Club
BCEL
InvestorPlace13 July 2023

Tech companies in certain high-growth sectors like semiconductors, AI, and cloud predominantly drove this year's bull market. But while these giants made headlines, many penny stocks continued trading at bargain prices.

Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
Atreca, Inc. (BCEL) Q4 2022 Earnings Call Transcript
BCEL
Seeking Alpha29 March 2023

Atreca, Inc. (NASDAQ:BCEL ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Alex Gray - Head of Investor Relations John Orwin - CEO Tito Serafini - Chief Strategy Officer and Founder Philippe Bishop - Chief Medical Officer Stephen Gould - Chief Scientific Officer Herb Cross - Chief Financial Officer Conference Call Participants Divya Rao - Cowen Roger Song - Jefferies John Newman - Canaccord Tony Butler - EF Hutton Stephen Willey - Stifel Kemp Dolliver - Brookline Capital Operator Thank you for standing by. Welcome to the Atreca's Fourth Quarter and Year End 2022 Earnings Call.

Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
BCEL
GlobeNewsWire23 March 2023

Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101

FAQ

  • What is the primary business of Atreca?
  • What is the ticker symbol for Atreca?
  • Does Atreca pay dividends?
  • What sector is Atreca in?
  • What industry is Atreca in?
  • What country is Atreca based in?
  • When did Atreca go public?
  • Is Atreca in the S&P 500?
  • Is Atreca in the NASDAQ 100?
  • Is Atreca in the Dow Jones?
  • When was Atreca's last earnings report?
  • When does Atreca report earnings?
  • Should I buy Atreca stock now?

What is the primary business of Atreca?

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

What is the ticker symbol for Atreca?

The ticker symbol for Atreca is NASDAQ:BCEL

Does Atreca pay dividends?

No, Atreca does not pay dividends

What sector is Atreca in?

Atreca is in the Healthcare sector

What industry is Atreca in?

Atreca is in the Biotechnology industry

What country is Atreca based in?

Atreca is headquartered in United States

When did Atreca go public?

Atreca's initial public offering (IPO) was on 20 June 2019

Is Atreca in the S&P 500?

No, Atreca is not included in the S&P 500 index

Is Atreca in the NASDAQ 100?

No, Atreca is not included in the NASDAQ 100 index

Is Atreca in the Dow Jones?

No, Atreca is not included in the Dow Jones index

When was Atreca's last earnings report?

Atreca's most recent earnings report was on 27 June 2024

When does Atreca report earnings?

The date for Atreca's next earnings report has not been announced yet

Should I buy Atreca stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions